These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25763580)

  • 21. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent pathway mutations of splicing machinery in myelodysplasia.
    Yoshida K; Sanada M; Shiraishi Y; Nowak D; Nagata Y; Yamamoto R; Sato Y; Sato-Otsubo A; Kon A; Nagasaki M; Chalkidis G; Suzuki Y; Shiosaka M; Kawahata R; Yamaguchi T; Otsu M; Obara N; Sakata-Yanagimoto M; Ishiyama K; Mori H; Nolte F; Hofmann WK; Miyawaki S; Sugano S; Haferlach C; Koeffler HP; Shih LY; Haferlach T; Chiba S; Nakauchi H; Miyano S; Ogawa S
    Nature; 2011 Sep; 478(7367):64-9. PubMed ID: 21909114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dyserythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
    Taylor J; Lee SC
    Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing factor mutant myelodysplastic syndromes: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ineffective erythropoiesis in myelodysplastic syndrome].
    Iwama A
    Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
    Kataoka N; Matsumoto E; Masaki S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
    Harada H; Harada Y
    Cancer Sci; 2015 Apr; 106(4):329-36. PubMed ID: 25611784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Charting the "Splice" Routes to MDS.
    Obeng EA; Ebert BL
    Cancer Cell; 2015 May; 27(5):607-9. PubMed ID: 25965565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
    Li L; Xiao ZJ; Sun XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interpreting new molecular genetics in myelodysplastic syndromes.
    Abdel-Wahab O; Figueroa ME
    Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
    Zhang L; Padron E; Lancet J
    Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal.
    Xu JJ; Smeets MF; Tan SY; Wall M; Purton LE; Walkley CR
    Exp Hematol; 2019 Feb; 70():10-23. PubMed ID: 30408513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.